266 related articles for article (PubMed ID: 27250613)
1. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
5. [PCSK9 inhibitors: new treatment to lower cholesterol].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
7. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
Saußele T
Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
[TBL] [Abstract][Full Text] [Related]
8. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibitors.
Farnier M
Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
11. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Kohli P; Desai NR; Giugliano RP; Kim JB; Somaratne R; Huang F; Knusel B; McDonald S; Abrahamsen T; Wasserman SM; Scott R; Sabatine MS
Clin Cardiol; 2012; 35(7):385-91. PubMed ID: 22714699
[TBL] [Abstract][Full Text] [Related]
12. Promising new therapies for the treatment of hypercholesterolemia.
Valerio MG; Velayati A; Jain D; Aronow WS
Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
White CM
Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Betteridge DJ
Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
[TBL] [Abstract][Full Text] [Related]
15. [PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®].
Češka R
Vnitr Lek; 2015 Nov; 61(11):946-51. PubMed ID: 26652782
[TBL] [Abstract][Full Text] [Related]
16. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
17. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
18. [Antibodies in addition to statin therapy lowers LDL cholesterol].
Bossenmayer S
Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
[No Abstract] [Full Text] [Related]
19. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibitors--past, present and future.
Reiner Ž
Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
